Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 3946 AL 3960

Language skills in Parkinson's disease: state of the art

de Souza GB, Beber BC.

Dement Neuropsychol. 2026 Feb 6;20:e20250350. doi: 10.1590/1980-5764-DN-2025-0350. eCollection 2026.

Descriptive analysis of mortality due to Parkinson's disease and Alzheimer disease in Argentina

Molinatti F, de Gracia L, Oliva A.

Neurologia (Engl Ed). 2026 Oct;41(8):502084. doi: 10.1016/j.nrleng.2026.502084. Epub 2026 May 1.

Convergent molecular pathways to inherited Parkinson's disease

Pfeffer SR.

Curr Opin Cell Biol. 2026 Apr;99:102624. doi: 10.1016/j.ceb.2026.102624. Epub 2026 Feb 19.

Molecular mechanisms of PINK1/Parkin-mediated mitochondrial quality control

Bayne AN, Trempe JF.

Trends Biochem Sci. 2026 May;51(5):474-490. doi: 10.1016/j.tibs.2026.02.014. Epub 2026 Apr 16.

Therapeutic potential of neuroprotective plant extracts in Parkinson's disease

Luo S, Zhang L, Wu X, Wang J, Li Q, Chen W, Li R, Zhou L, Zhou N, Chen R, Xie Y, Guo P.

Front Neurosci. 2026 Apr 1;20:1813133. doi: 10.3389/fnins.2026.1813133. eCollection 2026.

RNA editing in Parkinson's disease: emerging mechanisms, translational potential, and current challenges

Liu S, Wu A.

Front Neurosci. 2026 May 15;20:1850954. doi: 10.3389/fnins.2026.1850954. eCollection 2026.

Potential Protection Against Parkinson's Disease by Ergothioneine-Nature's Multifactorial Neuroprotectant

Tng TJW, Cheah IK, Halliwell B, Lim KL.

Antioxidants (Basel). 2026 Apr 21;15(4):519. doi: 10.3390/antiox15040519.

Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm

Antonini A, Bentivoglio AR, Calandra-Buonaura G, Ceravolo R, Leta V, Pellecchia MT, Pilotto A, Nicoletti A.

Neurol Sci. 2026 May 14;47(6):492. doi: 10.1007/s10072-026-08978-6.

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

Padilla AL, Lanciego JL, Vila M, de Castro F, Pozo D, Rodríguez de Fonseca F, Serrano A, Sáez-Valero J, Núñez L, Villalobos C, Tapias V.

Acta Pharm Sin B. 2026 May;16(5):2645-2681. doi: 10.1016/j.apsb.2026.03.031. Epub 2026 Mar 20.

Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial

van der Linden C, Berger T, Dembek TA, Brandt GA, Strelow JN, Baldermann JC, Jergas H, Fink GR, Visser-Vandewalle V, Barbe MT, Petry-Schmelzer JN.

Brain Stimul. 2026 Mar-Apr;19(2):103061. doi: 10.1016/j.brs.2026.103061. Epub 2026 Feb 23.

Effectiveness of Cognitive Enhancement Programs in Parkinson's Disease Patients with Mild Cognitive Impairment: A Narrative Review

Petri MC, Messinis L, Konitsiotis S, Nasios G.

Adv Exp Med Biol. 2026;1487:1-12. doi: 10.1007/978-3-032-03398-7_1.

The irony of Parkinson's disease: Converging mechanisms of redox imbalance and ferroptosis

Cooke LE, Rocha E, DiMaio R, Straub AC, Fazzari M.

Redox Biol. 2026 May 27;95:104239. doi: 10.1016/j.redox.2026.104239. Online ahead of print.

Mitochondria-Associated MicroRNAs: Emerging Roles in the Pathogenesis of Parkinson's Disease

Catanesi M, Di Leandro L, Colasante M, Cimini A, D'Angelo M, Castelli V, Obreja CM, Ippoliti R.

Biomedicines. 2026 Jan 30;14(2):313. doi: 10.3390/biomedicines14020313.

Dietary Lipids and Lipid-Mediated Signaling Neurovascular Unit Dysfunction: Implications for Alzheimer's and Parkinson's Diseases Pathogenesis

Wei X, Wang X, Liu L, Hu Y, Li W, Xian X, Hu X.

Mol Neurobiol. 2026 Mar 28;63(1):532. doi: 10.1007/s12035-026-05825-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias